Speaking on the opening evening of IAS 2015, Julio Montaner, M.D., and Michel Sidibe made passionate calls for universal access to HIV treatment and the rapid global expansion of the use of HIV treatment as a prevention method.
Voluntary medical male circumcision needs to be specifically identified as central to bringing epidemic levels of new infections to an end.
Two exciting new developments in pre-exposure prophylaxis (PrEP) are a long-acting injectable form of tenofovir, as well as an insertable vaginal ring containing dapivirine.
Preliminary results from a prospective observational study in serodifferent gay couples reported no linked HIV transmissions when the HIV positive partner had an undetectable viral load, even when not using condoms.
Although the headline PrEP news at CROI 2015 went to the PROUD and IPERGAY studies, important additional PrEP trials covered implementation and alternative dosing with oral PrEP and disappointing news that tenofovir gel was not effective in African w...
A person living with HIV can transmit the virus during the first six months of starting treatment. Researchers suggest extra prevention strategies for mixed-status couples during this period before viral suppression is achieved.
Disappointing new study results have dealt a serious blow to hopes for a tenofovir-containing vaginal gel to help women protect themselves from HIV infection. Poor adherence appeared to be the primary reason for the gel's failure.
On the day before CROI 2015, the U.S. Women and PrEP Working Group strategized how to expand PrEP access for women. Gretchen Weiss, M.P.H., senior program analyst for the National Association of County and City Health Officials (NACCHO), showed how loc…
A six-week ad campaign on Grindr -- a popular dating app for MSM (men who have sex with men) -- resulted in 344 requests for OraQuick HIV self-test kits, showing high potential for social media campaigns to reach untested populations.
HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.